144
Participants
Start Date
September 26, 2023
Primary Completion Date
September 30, 2025
Study Completion Date
December 31, 2026
ADRX-0706
Antibody drug conjugate targeting Nectin-4
Moffitt Cancer Center, Tampa
Comprehensive Hematology Oncology, St. Petersburg
Sarah Cannon Cancer Network, Nashville
The Ohio State University Wexner Medical Center, Hilliard
Karmanos Cancer Institute, Detroit
Henry Ford Cancer, Detroit
START Midwest, Grand Rapids
Stephenson Cancer Center, Oklahoma City
University of Texas MD Anderson Cancer Center, Houston
START San Antonio, San Antonio
START Mountain Region, West Valley City
USC Norris Comprehensive Cancer Center, Los Angeles
UCLA, Los Angeles
Beijing University Third Hospital, Beijing
Fujian Cancer Hospital, Fujian
Sun Yat-sen University Cancer Center, Guangzhou
Hunan Cancer hospital, Hunan
Shandong Cancer Hospital, Jinan
Shanghai East Hospital, Shanghai
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Wuhan Union Hospital, Wuhan
Lead Sponsor
Adcentrx Therapeutics
INDUSTRY